Targeting PPARγ via SIAH1/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer
Chih-Chieh Tu, Tsung-Han Hsieh, Cheng-Ying Chu, Yu-Chen Lin, Bo-Jyun Lin, Chun-Han Chen · 2024
Read Targeting PPARγ via SIAH1/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer by Chih-Chieh Tu, Tsung-Han Hsieh, Cheng-Ying Chu, Yu-Chen Lin, Bo-Jyun Lin, Chun-Han Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11655661.txt.
Description
Chih-Chieh Tu and co-authors test a toad venom compound against luminal-type bladder cancer in a 2024 study. This cancer subtype leans on a fat-sensing protein, PPAR gamma, that drives growth and hides tumors from immune attack.
The compound, cinobufotalin, strongly cut survival and growth of luminal cancer cells while sparing normal bladder lining cells. It also shrank tumors in a mouse graft model. Treated cells showed classic death markers and enzyme activation. The drug lowered the fat-sensing protein and its targets, plus fat droplets inside cells. Restoring the protein rescued cells from death. The team traces the kill to forced protein tagging and disposal by two helper enzymes.
Catalog record
| CREATOR | Chih-Chieh Tu, Tsung-Han Hsieh, Cheng-Ying Chu, Yu-Chen Lin, Bo-Jyun Lin, Chun-Han Chen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |